Daniel Jackson is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1260 Independence Ave
Akron, OH 443101812
Telephone
234-312-2140Provider last certified this registry record 19 Sept 2024.
Clinical trials
- Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Registry of Asthma Characterization and Recruitment 3 (RACR3)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
30%Folate Analog Metabolic Inhibitor9.2%Methotrexate100%Part D≥174 patientsTNF inhibitor6.2%Humira(Cf) Pen47%Enbrel Sureclick41%Cimzia (2 Pack)7%Humira(Cf)6%Part D<11 patients+ 9 more classes in this area
Nervous system
23%Gabapentinoids8.3%Gabapentin72%Pregabalin28%Part D≥103 patientsSNRI5.4%Duloxetine Hcl93%Venlafaxine Hcl7%Part D<11 patients+ 9 more classes in this area
Musculoskeletal
15.8%Muscle Relaxant5.5%Cyclobenzaprine Hcl92%Methocarbamol8%Part D<11 patientsNonsteroidal Anti-inflammatory Drug4.9%Diclofenac Sodium47%Nabumetone26%Etodolac21%Sulindac6%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”